Ozempic & GLP-1 litigation — safety & in… | DrugsMonitor.com

Clinical summary and reported injury patterns for Ozempic & GLP-1 litigation. Links to FDA recalls and litigation overview. Not medical advice.

semaglutide, tirzepatide, Wegovy, Mounjaro, Rybelsus, gastroparesis, intestinal obstruction

Clinical context

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are alleged to cause severe gastroparesis, obstruction, gallbladder disease, and pancreatitis in some users.

Litigation context

MDL No. 3094 in the Eastern District of Pennsylvania; discovery and bellwether planning active into 2026.